Table 2.
Type of CVD Outcome by Intervention Group
| Physical Activity (N=818) | Successful Aging (N=817) |
|||||
|---|---|---|---|---|---|---|
|
| ||||||
| Outcome | Annualized Incidence Rate per 100py (95% CI)* |
n (%) |
Annualized Incidence Rate per 100py (95% CI)* |
n (%) |
HR (95% CI)** |
P- value |
| Total fatal or non-fatal cardiovascular disease*** | 6.2 | 121 | 5.6 | 113 | 1.10 | 0.49 |
| (5.2, 7.4) | (14.8) | (4.7, 6.8) | (13.8) | (0.85, 1.42) | ||
| Fatal or non-fatal myocardial infarction, stroke or cardiovascular death | 1.8 | 38 | 1.7 | 37 | 1.05 | 0.83 |
| (1.3, 2.5) | (4.6) | (1.3, 2.4) | (4.5) | (0.67, 1.66) | ||
| Cardiovascular death | 0.5 | 10 | 0.7 | 14 | 0.71 | 0.41 |
| (0.3, 0.9) | (1.2) | (0.4, 1.1) | (1.7) | (0.32, 1.60) | ||
| Myocardial infarction | 0.6 | 12 | 0.5 | 10 | 1.22 | 0.64 |
| (0.3, 1.0) | (1.5) | (0.3, 0.9) | (1.2) | (0.53, 2.83) | ||
| Silent Myocardial infarction | 1.7 | 35 | 1.8 | 38 | 0.92 | 0.71 |
| (1.2, 2.4) | (4.3) | (1.3, 2.5) | (4.7) | (0.58, 1.45) | ||
| Angina/symptomatic coronary artery disease | 0.8 | 16 | 0.5 | 10 | 1.64 | 0.22 |
| (0.5, 1.2) | (2.0) | (0.3, 0.9) | (12) | (0.74, 3.61) | ||
| Stroke | 0.9 | 19 | 1.0 | 21 | 0.94 | 0.85 |
| (0.6, 1.4) | (2.3) | (0.6, 1.5) | (2.6) | (0.51, 1.76) | ||
| Coronary Revascularization | 1.0 | 20 | 0.5 | 10 | 2.08 | 0.05 |
| (0.6, 1.5) | (2.4) | (0.3, 0.9) | (1.2) | (0.97, 4.45) | ||
| CHF | 1.3 | 28 | 1.3 | 27 | 1.06 | 0.84 |
| (0.9, 1.9) | (3.4) | (0.9, 1.9) | (3.3) | (0.62, 1.79) | ||
| Abdominal Aortic Aneurysm | 0.1 | 3 | 0.0 | 1 | 2.99 | 0.31 |
| (0.0, 0.4) | (0.4) | (0.0, 0.3) | (0.1) | (0.31, 28.76) | ||
| Peripheral Artery Disease | 0.2 | 5 | 0.3 | 6 | 0.85 | 0.78 |
| (0.1, 0.6) | (0.6) | (0.1, 0.6) | (0.7) | (0.26, 2.78) | ||
| Carotid Revascularization | 0.0 | 0 | 0.1 | 2 | 0.00 | 0.10 |
| (0.0, 0.0) | (0.0) | (0.0, 0.4) | (0.2) | (0.00, 0.0) | ||
| Transient Ischemic Attack | 0.3 | 6 | 0.2 | 5 | 1.24 | 0.72 |
| (0.1, 0.6) | (0.7) | (0.1, 0.6) | (0.6) | (0.38, 4.07) | ||
*
Incident event rates estimated from an exponential survival model.
**
HRs from a proportional hazards model stratified by clinical site and gender.
***
Fatal or nonfatal myocardial infarction, stroke, cardiovascular death, silent myocardial infarction, angina/symptomatic coronary artery disease, peripheral artery disease, abdominal aortic aneurysm (our pre-defined primary CVD endpoint). The total incidence N is the number of participants who develop any of these conditions during the trial and thus will differ from the sum of the disease-specific totals.